An ‘international consortium’ has reached a deal with Dutch blood company Sanquin to acquire 85% of its plasma products arm in the Netherlands and Belgium. ‘These have achieved cost savings and economies of scale that a national plasma-derived medicine manufacturer such as SPP cannot match,’ the company said in a statement. This requires a partnership.’ Small market ‘The Dutch market …
